Your browser doesn't support javascript.
loading
Correlation of serum level of squamous cell carcinoma antigen with severity of cutaneous psoriasis, assessed using the simplified psoriasis index.
Henry, D; Alkhars, A; Samimi, M; Dufour, D; Machet, L.
Afiliación
  • Henry D; Dermatology Department, Centre Hospitalier Régional Universitaire, Tours, France.
  • Alkhars A; Dermatology Department, Centre Hospitalier Régional Universitaire, Tours, France.
  • Samimi M; Dermatology Department, Centre Hospitalier Régional Universitaire, Tours, France; Laboratoire 'Biologie des Infections à Polyomavirus [Polyomavirus Infection Biology Laboratory], ISP1282 INRA, Université de Tours, Tours, France.
  • Dufour D; Laboratoire de Médecine nucléaire in Vitro (MNIV - In Vitro Nuclear Medicine Laboratory), Centre Hospitalier Régional Universitaire, Tours, France; UMR INSERM U1253, Université de Tours, Tours, France.
  • Machet L; Dermatology Department, Centre Hospitalier Régional Universitaire, Tours, France; UMR INSERM U1253, Université de Tours, Tours, France. Electronic address: machet@univ-tours.fr.
Ann Dermatol Venereol ; 151(1): 103246, 2024 Mar.
Article en En | MEDLINE | ID: mdl-38422600
ABSTRACT

BACKGROUND:

Squamous cell carcinoma antigen (SCCA) is a biomarker of disease progression in squamous cell carcinoma but also contributes to the pathogenesis of psoriasis. Eight previous studies have shown a correlation between psoriasis severity, assessed using the Psoriasis Assessment Severity Index or body surface area, and serum level of SCCA, mainly SCCA2, assessed by means of non-commercial tests. We examined the correlation between serum SCCA level, measured with a commercial kit, and psoriasis severity assessed using the Simplified Psoriasis Index (SPI).

METHODS:

We conducted a prospective, non-interventional, single-centre study at the University Hospital of Tours over 18 months. The primary endpoint was same-day measurement of serum SCCA level and the psoriasis severity score on the professional version of the SPI (proSPI-s) at both baseline and follow-up. Secondary endpoints were same-day measurement of serum SCCA level and the proSPI psychosocial score (proSPI-p), proSPI treatment score, Dermatology Life Quality Index (DLQI), and inflammation parameters (C-reactive protein level, neutrophil-to-lymphocyte ratio).

RESULTS:

We included 50 psoriasis patients. Serum SCCA level was correlated with the proSPI-s at baseline and follow-up (Spearman r = 0.686 and r = 0.674, p < 0.0001) for both. It was correlated with the proSPI-p and DLQI. Serum SCCA level was not correlated with either neutrophil-to-lymphocyte ratio (r = 0.083) or C-reactive protein level (r = 0.192).

CONCLUSION:

This study is the first to correlate serum SCCA level with proSPI-s. Moreover, SCCA was measured using a widely available kit. SCCA may be used to assess the severity of psoriasis.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Psoriasis / Proteína C-Reactiva / Serpinas / Antígenos de Neoplasias Límite: Humans Idioma: En Revista: Ann Dermatol Venereol Año: 2024 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Francia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Psoriasis / Proteína C-Reactiva / Serpinas / Antígenos de Neoplasias Límite: Humans Idioma: En Revista: Ann Dermatol Venereol Año: 2024 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Francia